Leaning on a well-characterized MPN patient cohort both at the pathological and genomic level, we identify the TGF-β/WNT/homeobox B7 (HOXB7) axis in MF patients’ MSCs that is efficiently targeted in vitro. Here, TGFB1 is linked to myeloproliferative disorder.